Paediatric neurology
How should a family decide about stem cell therapy in autism?
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Autism is where marketing pressure on families is heaviest. This framework is written to help you say no as easily as yes.
- Medically reviewed by:
- Prof. Dr. Erdal Karaöz, PhD
- Last reviewed:
- Next review:
The short answer
Published human studies in autism are small, heterogeneous and mostly uncontrolled, and the outcome scales used are subjective. Some randomised work exists and reports modest changes in behavioural scales, with no evidence that core autism is cured. We only discuss treatment alongside continuing behavioural and educational therapy, never instead of it.
Who this decision applies to
Usually appropriate to discuss
- Formal diagnosis by a paediatric neurologist or developmental paediatrician
- Established behavioural, speech and educational therapy already in place
- Parents who understand the outcome measures are subjective and the evidence is early
- Capacity to attend structured, dated follow-up assessments
Not appropriate right now
- Families told to pause established therapies during treatment
- Children with unexplained regression that has not been fully investigated
- Expectation of a cure, or of speech appearing on a promised timetable
- Any protocol involving unlicensed products or undisclosed cell sources
Evidence at a glance
The same five questions we ask of every indication, answered for this one.
| Question | Answer | What that means here |
|---|---|---|
| Human studies published? | Yes | Human studies including some randomised trials have been published. |
| Randomised controlled trials? | Limited | Randomised trials exist but are few, small and inconsistent in design. |
| Objective outcome measures? | Partly | CARS, ATEC and ABC scales are used; all rely on observer judgement. |
| Long-term follow-up (≥12 months)? | Limited | Long-term developmental follow-up is largely absent. |
| Approved as a routine therapy? | No | No regulatory approval for cell therapy in autism in any major jurisdiction. |
How these judgements are made: How we evaluate evidence · Editorial standards · Conflict-of-interest disclosure.
Options compared, including doing nothing
| Option | What it can realistically do | Main trade-off |
|---|---|---|
| Intensive behavioural and speech therapy | The best-evidenced intervention for developmental progress | Time-intensive and expensive over years |
| Medical management of comorbidities | Sleep, seizures and GI problems often improve function most | Does not address core features |
| Cell therapy as an adjunct | Under study; reported changes are modest and variable | Cost, travel and no guarantee of any change |
| Wait and reassess | Avoids exposing a child to an unproven intervention | Families often find waiting hardest |
How the decision is made in practice
- We ask for the diagnostic report, current therapy schedule and any recent scale scores.
- We check that comorbidities such as epilepsy, sleep disorder and GI disease have been addressed first.
- We ask parents to describe the change they are hoping for, and we say plainly whether it is realistic.
- Baseline scales are recorded before treatment and repeated by the same assessor afterwards.
- Behavioural and educational therapy continues throughout; that is a condition of treatment.
When we decline, and why
- Where established therapies have not been tried or would be paused
- Where a cure is expected, or the family cannot accept a null result
- Unstable epilepsy or other uncontrolled medical conditions
- Regression that has not been neurologically investigated
Declining is a normal outcome of assessment, not a failure of it. See how candidacy and redirection work.
Questions worth asking any clinic
- Which scales will be used, who administers them, and are they the same person before and after?
- What did the randomised trials in autism actually report, and over what period?
- What is the source, dose and release testing of the cells?
- What will you tell me if nothing changes?
Frequently asked questions
No. There is no published evidence of cure, and any clinic implying otherwise is misrepresenting the literature. Published trials report modest, variable changes on behavioural scales in some children and no change in others.
We cannot promise that, and we do not. Speech development in young children continues with therapy regardless of any intervention, which is exactly why uncontrolled reports are so unreliable in this indication.
No, and we would decline to treat if that were the plan. Established therapy is the intervention with real evidence behind it; nothing we do should interrupt it.
Sources
- stem cell therapy autism spectrum disorder randomized controlled trial — Randomised trials of cell therapy in autism.
- umbilical cord blood autism spectrum disorder trial — Cord-blood studies and their outcome measures.
- cell therapy autism spectrum disorder — Registered trials in autism.
Citation practice and source hierarchy: How we evaluate evidence.
Related clinical questions
- Autism programme overview
- How candidacy and redirection work
- How we evaluate evidence
- Editorial standards
Want this reviewed for your own case?
Send your diagnosis, imaging and medication list. If the answer is no, we will say so and explain why.
How to cite this page
This page's evidence table is published under CC BY 4.0. Reuse it with attribution and a link back.
| Style | Citation |
|---|---|
| APA | StemCell Longevita. (2026). How should a family decide about stem cell therapy in autism?. StemCell Longevita. https://stemcelllongevita.com/clinical-decisions/autism-family-decision-framework |
| Vancouver | StemCell Longevita. How should a family decide about stem cell therapy in autism? [Internet]. Istanbul: StemCell Longevita; 2026 [cited 2026-08-23]. Available from: https://stemcelllongevita.com/clinical-decisions/autism-family-decision-framework |
BibTeX:
@techreport{longevita_autism_family_decision_framework_2026,
title = {How should a family decide about stem cell therapy in autism?},
author = {{StemCell Longevita}},
institution = {StemCell Longevita},
year = {2026},
url = {https://stemcelllongevita.com/clinical-decisions/autism-family-decision-framework},
urldate = {2026-08-23}
}Structured data: The evidence table on this page is also published as a machine-readable dataset descriptor. /cite